Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to further investigate whether striatal [11C]ORM-13070
uptake can be reduced by physiological and pharmacological challenges that increase the
synaptic concentrations of noradrenaline in the human brain. Each subject will undergo 3 PET
scans, a baseline PET scan and two scans with noradrenaline challenges: intravenous
administration of ketamine and oral administration of atomoxetine combined with a cold
pressor test where the subject's foot is placed in an 8 °C water basin. Eight healthy male
subjects will be included in the study.
Phase:
Phase 1
Details
Lead Sponsor:
University of Turku
Collaborators:
Orion Corporation, Orion Pharma Turku University Hospital